JPRN-jRCTs051190014已完成4 期
On target management for secondary hyperparathyroidism by two calcimimetics - HP2C study
Kuragano Takahiro0 个研究点目标入组 300 人开始时间: 2019年5月9日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Maintenance hemodialysis patients with secondary hyperparathyroidism (int-PTH>240 pg/mL)
排除标准
- •Patients with sever heart failure (>NYHA III),liver dysfunction, respiratory failure, and malignant tumor.
研究者
相似试验
尚未招募
不适用
On target management for secondary hyperparathyroidism by two calcimimetics (HP2C study)Chronic kidney diseaseJPRN-UMIN000029000Hyogo College of Medicine300
进行中（未招募）
不适用
Behandling af sekundær hyperparathyreoidisme hos uræmiske patienter.En sammenlignenede undersøgelse mellem virkningen af alfacalcidol og paricalcitol.EUCTR2006-005981-37-DKRoskilde Amts Sygehus
进行中（未招募）
不适用
TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET - NDPrimary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)MedDRA version: 9.1Level: LLTClassification code 10027180EUCTR2008-005055-23-ITOSPEDALE MAGGIORE DI MILANO (IRCCS)
已完成
不适用
Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic NephropathySecondary HyperparathyroidismDiabetic NephropathiesNCT03137316Benha University437
撤回
不适用
Surgical Approach for Primary Hyperparathyroidism in the ElderlyMultigland Disease in Primary HyperparathyroidismNCT01484379Rambam Health Care Campus